< Back to all news
13 May 2024

Revolutionizing Liver Disease Prognosis: Insights from Vibration-Controlled Transient Elastography

Welcome to a new insightful episode of “Ask the Author”. Today, we’re honored to have Professor Vincent Wong with us, discussing his groundbreaking work titled “Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease,” recently published in JAMA.

In this enlightening discussion, Professor Wong delves into the background and context of their study. He highlights the prevalence of Metabolic Associated Fatty Liver Disease (MAFLD), affecting over 30% of the global population, necessitating the use of noninvasive tests (NITs) for disease assessment. Unlike previous studies focused solely on the correlation between NITs and liver histology, Professor Wong’s team aimed to demonstrate the prognostic value of NITs in monitoring disease progression and treatment response.

Their study, a multicenter cohort involving over 16,000 patients with MAFLD, showcased impressive numbers. Prospective data collection across 16 tertiary referral centers allowed for longitudinal analysis, with more than 10,000 patients undergoing multiple examinations. This comprehensive approach provided insights into the prognostic significance of changes in NITs over time.

The results are nothing short of revolutionary. Many existing NITs exhibited prognostic performance comparable to, if not superior to, liver histology. Notably, the Vibration-Controlled Transient Elastography (VCTE)-based Agile 3+ and Agile 4 scores stood out, boasting time-dependent area under the curve values nearing 90%. Furthermore, a 20% or greater change in liver status measurement translated into significant alterations in the incidence of liver-related events, validating NITs as effective monitoring tools.

Professor Wong emphasizes the transformative impact of these findings on the field. With growing evidence supporting the efficacy of NITs in predicting liver-related events and monitoring disease progression, the need for liver biopsy for prognostication diminishes. As regulatory bodies consider NITs as surrogate endpoints, patients stand to benefit from reduced reliance on invasive procedures, both in research and routine clinical care.

In conclusion, Professor Wong’s study heralds a new era in liver disease management, where noninvasive tests serve as reliable indicators of prognosis. With these insights, medical practitioners can navigate the complexities of MAFLD with greater confidence and precision, ultimately improving patient outcomes.

We extend our heartfelt congratulations to Professor Wong and his team for their remarkable contribution to the field. Stay tuned for more enlightening discussions on cutting-edge medical research.

Prof. Vincent Wong answering to the questions of Professor Jean-François Dufour.

< Back to all news
1 May 2024

Unlocking Insights: Highlights from HCC Day 2024

Dear Medical Colleagues,

In the ever-evolving landscape of hepatocellular carcinoma (HCC) management, staying abreast of the latest advancements is paramount. Fortunately, the recent HCC Day 2024 provided an invaluable platform for knowledge exchange, featuring esteemed international experts who shared groundbreaking insights and strategies in the fight against HCC.

We are excited to announce that the video content from this exceptional event is now available for viewing. Delve into a wealth of expertise and innovation by accessing the recordings at HCC Day 2024 webcast.

Here are just a few highlights from the keynote presentations:

  1. Selecting Systemic Therapy for HCC – Dr. A. Saborowski offers invaluable guidance on navigating the complex landscape of systemic therapy selection, providing practical insights for optimizing patient outcomes.
  2. TACE with I/O for HCC – Dr. R. Lencioni explores the promising frontier of combining transarterial chemoembolization (TACE) with immunotherapy, shedding light on novel approaches to HCC treatment.
  3. Combining Chemotherapy and Immunotherapy for Biliary Tract Cancer – Dr. K. Kelley shares groundbreaking research on the integration of chemotherapy and immunotherapy as a first-line approach for biliary tract cancer, offering new hope for patients facing this challenging disease.
  4. Systemic Therapies in Phase 2 to Treat HCC – Dr. R. Finn provides invaluable insights into emerging systemic therapies in phase 2 trials, highlighting potential game-changers in the field of HCC management.
  5. Preventing HCC Recurrence after Curative Therapy – Dr. P. Galle presents strategies for preventing HCC recurrence following curative therapy, addressing a critical aspect of long-term patient care.

Whether you’re a seasoned oncologist, a hepatologist, or a healthcare professional with an interest in HCC, these presentations are a must-watch. Gain access to cutting-edge research, clinical strategies, and expert perspectives that can inform and enhance your practice.

Don’t miss out on this unparalleled opportunity to expand your knowledge and elevate patient care. Click here to access the full spectrum of presentations from HCC Day 2024, thanks to Klewel audiovisual, streaming and webcasting services.

Quick recap of the HCC Day 2024.

Yours in advancing HCC care,

Professor Jean-François Dufour / NASH Foundation